Cite
Mates M, Fletcher GG, Freedman OC, et al. Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol. 2015;22:S114-22doi: 10.3747/co.22.2322.
Mates, M., Fletcher, G. G., Freedman, O. C., Eisen, A., Gandhi, S., Trudeau, M. E., & Dent, S. F. (2015). Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Current oncology (Toronto, Ont.), 22S114-22. https://doi.org/10.3747/co.22.2322
Mates, M, et al. "Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline." Current oncology (Toronto, Ont.) vol. 22 (2015): S114-22. doi: https://doi.org/10.3747/co.22.2322
Mates M, Fletcher GG, Freedman OC, Eisen A, Gandhi S, Trudeau ME, Dent SF. Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol. 2015 Mar;22:S114-22. doi: 10.3747/co.22.2322. PMID: 25848335; PMCID: PMC4381787.
Copy
Download .nbib